129 related articles for article (PubMed ID: 38927219)
1. Optimizing Antibiotic Therapy for
Barrasa H; Morán MA; Fernández-Ciriza L; Isla A; Solinís MÁ; Canut-Blasco A; Rodríguez-Gascón A
Antibiotics (Basel); 2024 Jun; 13(6):. PubMed ID: 38927219
[No Abstract] [Full Text] [Related]
2. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
Wei C; Ni W; Cai X; Cui J
Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020.
Lee YL; Liu CE; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106878. PubMed ID: 37285926
[TBL] [Abstract][Full Text] [Related]
4. Treatment approaches for severe Stenotrophomonas maltophilia infections.
Mojica MF; Bonomo RA; van Duin D
Curr Opin Infect Dis; 2023 Dec; 36(6):572-584. PubMed ID: 37846568
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
Asín E; Isla A; Canut A; Rodríguez Gascón A
Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
[TBL] [Abstract][Full Text] [Related]
6. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
Méndez-Sotelo BJ; Delgado-Beltrán M; Hernández-Durán M; Colín-Castro CA; Esquivel-Bautista J; Ortega-Oliva SA; Ortiz-Álvarez J; García-Contreras R; Franco-Cendejas R; Lopez Jacome LE
PLoS One; 2024; 19(4):e0298577. PubMed ID: 38635685
[TBL] [Abstract][Full Text] [Related]
8. Steno-sphere: Navigating the enigmatic world of emerging multidrug-resistant Stenotrophomonas maltophilia.
Kunz Coyne AJ; Herbin S; Caniff K; Rybak MJ
Pharmacotherapy; 2023 Aug; 43(8):833-846. PubMed ID: 37199104
[TBL] [Abstract][Full Text] [Related]
9. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
[No Abstract] [Full Text] [Related]
10. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
[TBL] [Abstract][Full Text] [Related]
11.
Huang YS; Chuang YC; Chen PY; Chou PC; Wang JT
JAC Antimicrob Resist; 2024 Feb; 6(1):dlae006. PubMed ID: 38304722
[TBL] [Abstract][Full Text] [Related]
12. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
13. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
Kispal B; Walker SAN
Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
[TBL] [Abstract][Full Text] [Related]
14.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
15. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
[TBL] [Abstract][Full Text] [Related]
16. Looking for
Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
[TBL] [Abstract][Full Text] [Related]
17. Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated
Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Andes D; Arendrup MC; Mouton JW; Meletiadis J
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229492
[TBL] [Abstract][Full Text] [Related]
18. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
[TBL] [Abstract][Full Text] [Related]
19. Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Bostanghadiri N; Sholeh M; Navidifar T; Dadgar-Zankbar L; Elahi Z; van Belkum A; Darban-Sarokhalil D
Ann Clin Microbiol Antimicrob; 2024 Mar; 23(1):26. PubMed ID: 38504262
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
Frei CR; Wiederhold NP; Burgess DS
J Antimicrob Chemother; 2008 Mar; 61(3):621-8. PubMed ID: 18252694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
